AR095198A1 - Derivados de triazolona de piridinilo y piridinilo fusionado - Google Patents
Derivados de triazolona de piridinilo y piridinilo fusionadoInfo
- Publication number
- AR095198A1 AR095198A1 ARP140100805A ARP140100805A AR095198A1 AR 095198 A1 AR095198 A1 AR 095198A1 AR P140100805 A ARP140100805 A AR P140100805A AR P140100805 A ARP140100805 A AR P140100805A AR 095198 A1 AR095198 A1 AR 095198A1
- Authority
- AR
- Argentina
- Prior art keywords
- independently selected
- halo
- alkyl
- optionally substituted
- hydrogen
- Prior art date
Links
- 125000005843 halogen group Chemical group 0.000 abstract 17
- 125000001424 substituent group Chemical group 0.000 abstract 14
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 13
- 229910052739 hydrogen Inorganic materials 0.000 abstract 12
- 239000001257 hydrogen Substances 0.000 abstract 12
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 9
- 125000004043 oxo group Chemical group O=* 0.000 abstract 8
- 150000002431 hydrogen Chemical group 0.000 abstract 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 6
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 abstract 5
- 125000004432 carbon atom Chemical group C* 0.000 abstract 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 125000003386 piperidinyl group Chemical group 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 2
- -1 R10 Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 101100240518 Caenorhabditis elegans nhr-12 gene Proteins 0.000 abstract 1
- 101100079984 Caenorhabditis elegans nhr-9 gene Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
Las composiciones farmacéuticas del compuesto son útiles para enfermedades autoinmunes; trastornos inflamatorios, cáncer, trastornos proliferativos no malignos; y otras afecciones asociadas con BTK. Reivindicación 1: Un compuesto de fórmula (1), un tautómero del mismo o una sal farmacéuticamente aceptable del compuesto o tautómero, en donde: R¹ se selecciona de hidrógeno, halo, -CN, alquilo C₁₋₄, haloalquilo C₁₋₄, y -OR¹⁴; R² y R³ son cada uno independientemente seleccionados de hidrógeno, halo, -CN, R⁶, y R⁷, o R² y R³, junto con átomos de carbono a los cuales están unidos, forman un anillo de benceno o un anillo de piridino en donde el anillo de benceno está opcionalmente sustituido con de uno a cuatro sustituyentes independientemente seleccionados de halo, -CN, R⁶, y R⁷, y el anillo de piridina está opcionalmente sustituido con de uno a tres sustituyentes independientemente seleccionados de halo, -CN, R⁶, y R⁷; R⁴ tiene la fórmula (2), en donde la línea ondulada indica un punto de unión; L se selecciona de -O-, -CH₂O-, y -N(R⁴ᵉ)-; R⁴ᵃ se selecciona de -CH₂R⁵ y etenil opcionalmente sustituido con de uno a tres sustituyentes independientemente seleccionados de halo, ciano, y R⁷; y (a) R⁴ᶜ es hidrógeno, R⁴ᵉ se selecciona de hidrógeno y alquilo C₁₋₄ cuando L es -N(R⁴ᵉ)-, y R⁴ᵇ y R⁴ᵈ, junto con un átomo de nitrógeno y átomos de carbono a los cuales R⁴ᵇ, R⁴ᶜ, y R⁴ᵈ están respectivamente unidos, forman un anillo de pirrolidina o un anillo de piperidina, cada anillo opcionalmente sustituido con de uno a seis sustituyentes independientemente seleccionados de halo, alquilo C₁₋₄ ,y haloalquilo C₁₋₄; o (b) R⁴ᵇ se selecciona de hidrógeno y alquilo C₁₋₄, R⁴ᵈ es hidrógeno, L es -N(R⁴ᵉ)-, y R⁴ᶜ y R⁴ᵉ, junto con los átomos de carbono y un átomo de nitrógeno a los cuales R⁴ᶜ, R⁴ᵈ, y R⁴ᵉ están respectivamente unidos, forman un anillo de pirrolidina o un anillo de piperidina, cada anillo opcionalmente sustituido con de uno a seis sustituyentes independientemente seleccionados de halo, alquilo C₁₋₄, y haloalquilo C₁₋₄; o (c) R⁴ᵈ es hidrógeno, R⁴ᵉ se selecciona de hidrógeno y alquilo C₁₋₄ cuando L es -N(R⁴ᵉ)-, y R⁴ᵇ y R⁴ᶜ, junto con el nitrógeno y átomos de carbono a los cuales R⁴ᵇ y R⁴ᶜ están respectivamente unidos, forman un anillo de pirrolidina o un anillo de piperidina, cada anillo opcionalmente sustituido con de uno a seis sustituyentes independientemente seleccionados de halo, alquilo C₁₋₄, y haloalquilo C₁₋₄; R⁵ se selecciona de hidrógeno, halo, y alquilo C₁₋₄; cada R⁶ se selecciona de manera independiente de -OR⁸, -N(R⁸)R⁹, -NR⁸C(O)R⁹, -NHC(O)NR⁸R⁹, -NR⁸C(O)NHR⁹, -C(O)R⁸, -C(O)OR⁸, -C(O)N(R⁸)R⁹, -C(O)N(R⁸)OR⁹, -C(O)N(R⁸)S(O)₂R⁷, -N(R⁸)S(O)₂R⁷, -SR⁸, -S(O)R⁷, -S(O)₂R⁷, y-S(O)₂N(R⁸)R⁹; cada R⁷ se selecciona de manera independiente de (a) alquilo C₁₋₆, alquenilo C₂₋₆, y alquinilo C₂₋₆, cada uno opcionalmente sustituido con de uno a cinco sustituyentes independientemente seleccionados de halo, oxo, -CN, y R¹⁰; y (b) cicloalquilo C₃₋₁₀-(CH₂)ₘ-, arilo C₆₋₁₄-(CH₂)ₘ-, heterociclilo C₂₋₆-(CH₂)ₘ-, y heteroarilo C₁₋₉-(CH₂)ₘ-, cada uno opcionalmente sustituido con de uno a cinco sustituyentes independientemente seleccionados de halo, oxo, -CN, R¹⁰, y alquilo C₁₋₆ opcionalmente sustituido con de uno a cinco sustituyentes independientemente seleccionados de halo, oxo, -CN, y R¹⁰; cada R⁸ y R⁹ se selecciona de manera independiente de (a) hidrógeno; (b) alquilo C₁₋₆, alquenilo C₂₋₆, y alquinilo C₂₋₆, cada uno opcionalmente sustituido con de uno a cinco sustituyentes independientemente seleccionados de halo, oxo, -CN, y R¹⁰; y (c) cicloalquilo C₃₋₁₀-(CH₂)ₘ-, arilo C₆₋₁₄-(CH₂)ₘ-, heterociclilo C₂₋₆-(CH₂)ₘ-, y heteroarilo C₁₋₉-(CH₂)ₘ-, cada uno opcionalmente sustituido con de uno a cinco sustituyentes independientemente seleccionados de halo, oxo, -CN, R¹⁰, y alquilo C₁₋₆ opcionalmente sustituido con de uno a cinco sustituyentes independientemente seleccionados de halo, oxo, -CN, y R¹⁰; cada R¹⁰ se selecciona de manera independiente de -OR¹¹, -N(R¹¹)R¹², -N(R¹¹)C(O)R¹², -NHC(O)NR¹¹R¹², -NR¹¹C(O)NHR¹², -C(O)R¹¹, -C(O)OR¹¹, -C(O)N(R¹¹)R¹², -C(O)N(R¹¹)OR¹², -C(O)N(R¹¹)S(O)₂R¹³, -NR¹¹S(O)₂R¹³, -SR¹¹, -S(O)R¹³, -S(O)₂R¹³, y -S(O)₂N(R¹¹)R¹²; cada R¹¹ y R¹² se selecciona de manera independiente de (a) hidrógeno; y (b) alquilo C₁₋₆ y cicloalquilo C₃₋₁₀-(CH₂)ₘ-, cada uno opcionalmente sustituido con de uno a cinco sustituyentes independientemente seleccionados de halo, oxo, -CN, -OH, y -NH₂; cada R¹³ se selecciona de manera independiente de alquilo C₁₋₆ y cicloalquilo C₃₋₁₀-(CH₂)ₘ-, cada uno opcionalmente sustituido con de uno a cinco sustituyentes independientemente seleccionados de halo, oxo, -CN, -OH, y-NH₂; cada R¹⁴ se selecciona de manera independiente de hidrógeno, alquilo C₁₋₄, y haloalquilo C₁₋₄; y cada m se selecciona de manera independiente de 0, 1, 2, 3, y 4; en donde cada heteroarilo y heterociclilo de R⁷, R⁸, y R⁹ independientemente tiene de uno a cuatro heteroátomos, cada uno de los heteroátomos independientemente seleccionados de N, O, y S.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361776445P | 2013-03-11 | 2013-03-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR095198A1 true AR095198A1 (es) | 2015-09-30 |
Family
ID=50543655
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP140100805A AR095198A1 (es) | 2013-03-11 | 2014-03-10 | Derivados de triazolona de piridinilo y piridinilo fusionado |
Country Status (42)
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2731833T3 (es) | 2012-09-10 | 2019-11-19 | Principia Biopharma Inc | Compuestos pirazolopirimidínicos comos inhibidores de cinasas |
JO3377B1 (ar) * | 2013-03-11 | 2019-03-13 | Takeda Pharmaceuticals Co | مشتقات بيريدينيل وبيريدينيل مندمج |
SG11201606858RA (en) | 2014-02-21 | 2016-09-29 | Principia Biopharma Inc | Salts and solid form of a btk inhibitor |
CN104447530A (zh) * | 2014-12-11 | 2015-03-25 | 苏州欧凯医药技术有限公司 | 4-甲基-2,6-二羧基吡啶的制备方法 |
MA41197B1 (fr) * | 2014-12-18 | 2021-01-29 | Principia Biopharma Inc | Traitement de le pemphigus |
US20180305350A1 (en) | 2015-06-24 | 2018-10-25 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
SG11201805331QA (en) * | 2015-12-24 | 2018-07-30 | Takeda Pharmaceuticals Co | Cocrystal, production method thereof, and medicament containing cocrystal |
DK3402503T3 (da) * | 2016-01-13 | 2020-12-21 | Acerta Pharma Bv | Terapeutiske kombinationer af et antifolat og en btk-hæmmer |
AU2017240609B2 (en) * | 2016-03-31 | 2021-07-15 | Takeda Pharmaceutical Company Limited | Isoquinolinyl triazolone complexes |
IL263815B (en) | 2016-06-29 | 2022-07-01 | Principia Biopharma Inc | Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(Oxtan-3-yl)piperazin-1-yl)pent-2-ananitrile |
CN112424207B (zh) | 2018-07-25 | 2024-03-19 | 诺华股份有限公司 | Nlrp3炎性小体抑制剂 |
AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
CA3135943A1 (en) * | 2019-04-02 | 2020-10-08 | Yonsei University, University-Industry Foundation (UIF) | Novel compound and method for preventing or treating of respiratory disease comprising the same as an active ingredient |
AR119731A1 (es) | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
WO2022034529A1 (en) | 2020-08-14 | 2022-02-17 | Novartis Ag | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof |
US20240067627A1 (en) | 2022-08-03 | 2024-02-29 | Novartis Ag | Nlrp3 inflammasome inhibitors |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
US5733849A (en) * | 1996-03-15 | 1998-03-31 | Rohm And Haas Company | Halopyridyl triazolinone herbicides and herbicidal use thereof |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
JP2002512216A (ja) | 1998-04-17 | 2002-04-23 | パーカー ヒューズ インスティテュート | Btkインヒビターならびにその同定方法および使用方法 |
AU2001292670A1 (en) * | 2000-09-15 | 2002-03-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
ATE318812T1 (de) | 2000-12-21 | 2006-03-15 | Bristol Myers Squibb Co | Thiazolyl-inhibitoren von tyrosinkinasen der tec- familie |
US7572809B2 (en) * | 2005-12-19 | 2009-08-11 | Hoffmann-La Roche Inc. | Isoquinoline aminopyrazole derivatives |
MX2008008642A (es) | 2006-01-13 | 2008-09-12 | Pharmacyclics Inc | Inhibidores de las tirosina cinasas y usos de los mismos. |
AU2007267859B2 (en) * | 2006-05-25 | 2012-04-12 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate Hsp90 activity |
WO2007147771A2 (en) | 2006-06-20 | 2007-12-27 | F. Hoffmann-La Roche Ag | Tetralin and indane derivatives and uses thereof |
AR063946A1 (es) | 2006-09-11 | 2009-03-04 | Cgi Pharmaceuticals Inc | Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden. |
EP2081435B1 (en) | 2006-09-22 | 2016-05-04 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
EP2560007A1 (en) | 2007-03-28 | 2013-02-20 | Pharmacyclics, Inc. | Identification of bruton's tyrosine kinase inhibitors |
CN101952283B (zh) | 2007-12-14 | 2013-04-17 | 霍夫曼-拉罗奇有限公司 | 咪唑并[1,2-a]吡啶和咪唑并[1,2-b]哒嗪衍生物 |
CN101932573B (zh) | 2008-02-05 | 2014-06-11 | 霍夫曼-拉罗奇有限公司 | 吡啶酮类和哒嗪酮类 |
CA2728016C (en) | 2008-06-24 | 2017-02-28 | F. Hoffmann-La Roche Ag | Novel substituted pyridin-2-ones and pyridazin-3-ones |
PE20110164A1 (es) | 2008-07-02 | 2011-03-28 | Hoffmann La Roche | Nuevas fenilpirazinonas como inhibidores de quinasa |
JP5318952B2 (ja) | 2008-07-15 | 2013-10-16 | エフ.ホフマン−ラ ロシュ アーゲー | 新規なフェニル−イミダゾピリジン類及びピリダジン類 |
US8598174B2 (en) | 2008-11-12 | 2013-12-03 | Genetech, Inc. | Pyridazinones, method of making, and method of use thereof |
WO2010068810A2 (en) | 2008-12-10 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
WO2010068788A1 (en) * | 2008-12-10 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Heterocyclic amides as btk inhibitors |
EP2569302A1 (en) | 2010-05-13 | 2013-03-20 | Amgen, Inc | Heteroaryloxyheterocyclyl compounds as pde10 inhibitors |
WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
AR083267A1 (es) * | 2010-10-04 | 2013-02-13 | Novartis Ag | Combinaciones farmaceuticas |
BR112013010957A2 (pt) | 2010-10-20 | 2016-08-30 | Gruenenthal Gmbh | 6-amino-nicotinamidas substituídas como moduladores kcnq2/3 |
EP2637816A4 (en) | 2010-11-10 | 2017-07-26 | Stc.Unm | Aerosol reduction/expansion synthesis (a-res) for zero valent metal particles |
JO3377B1 (ar) | 2013-03-11 | 2019-03-13 | Takeda Pharmaceuticals Co | مشتقات بيريدينيل وبيريدينيل مندمج |
-
2014
- 2014-03-05 JO JOP/2014/0070A patent/JO3377B1/ar active
- 2014-03-10 AU AU2014249248A patent/AU2014249248B2/en active Active
- 2014-03-10 KR KR1020157028600A patent/KR102300612B1/ko active IP Right Grant
- 2014-03-10 TW TW103108214A patent/TWI637950B/zh active
- 2014-03-10 PE PE2015001905A patent/PE20151889A1/es active IP Right Grant
- 2014-03-10 RS RS20170414A patent/RS55879B1/sr unknown
- 2014-03-10 EA EA201591686A patent/EA028584B1/ru unknown
- 2014-03-10 EP EP14719130.8A patent/EP2970202B1/en active Active
- 2014-03-10 SG SG11201506112QA patent/SG11201506112QA/en unknown
- 2014-03-10 WO PCT/US2014/022801 patent/WO2014164558A1/en active Application Filing
- 2014-03-10 MY MYPI2015703082A patent/MY183927A/en unknown
- 2014-03-10 ME MEP-2017-98A patent/ME02693B/me unknown
- 2014-03-10 PT PT147191308T patent/PT2970202T/pt unknown
- 2014-03-10 DK DK14719130.8T patent/DK2970202T3/en active
- 2014-03-10 UY UY0001035376A patent/UY35376A/es not_active Application Discontinuation
- 2014-03-10 GE GEAP201413953A patent/GEP201706778B/en unknown
- 2014-03-10 MX MX2015011533A patent/MX364527B/es active IP Right Grant
- 2014-03-10 PL PL14719130T patent/PL2970202T3/pl unknown
- 2014-03-10 AR ARP140100805A patent/AR095198A1/es active IP Right Grant
- 2014-03-10 CA CA2899948A patent/CA2899948C/en active Active
- 2014-03-10 LT LTEP14719130.8T patent/LT2970202T/lt unknown
- 2014-03-10 ES ES14719130.8T patent/ES2624439T3/es active Active
- 2014-03-10 HU HUE14719130A patent/HUE032720T2/en unknown
- 2014-03-10 ES ES17152008T patent/ES2714166T3/es active Active
- 2014-03-10 EP EP17152008.3A patent/EP3235814B1/en active Active
- 2014-03-10 JP JP2016501072A patent/JP6271700B2/ja active Active
- 2014-03-10 BR BR112015020264-0A patent/BR112015020264B1/pt active IP Right Grant
- 2014-03-10 SI SI201430203A patent/SI2970202T1/sl unknown
- 2014-03-10 UA UAA201507597A patent/UA114944C2/uk unknown
- 2014-03-10 AP AP2015008646A patent/AP2015008646A0/xx unknown
- 2014-03-10 US US14/203,366 patent/US9402841B2/en active Active
- 2014-03-10 CN CN201480012902.5A patent/CN105121427B/zh active Active
- 2014-03-10 MA MA38391A patent/MA38391B1/fr unknown
-
2015
- 2015-08-04 IL IL240353A patent/IL240353B/en active IP Right Grant
- 2015-08-06 DO DO2015000184A patent/DOP2015000184A/es unknown
- 2015-08-11 TN TN2015000342A patent/TN2015000342A1/en unknown
- 2015-08-19 ZA ZA2015/05996A patent/ZA201505996B/en unknown
- 2015-08-24 CL CL2015002370A patent/CL2015002370A1/es unknown
- 2015-09-10 PH PH12015502046A patent/PH12015502046B1/en unknown
- 2015-09-10 CR CR20150470A patent/CR20150470A/es unknown
- 2015-10-08 EC ECIEPI201542779A patent/ECSP15042779A/es unknown
-
2016
- 2016-06-29 US US15/197,051 patent/US9801872B2/en active Active
- 2016-07-12 HK HK16108174.3A patent/HK1220183A1/zh unknown
-
2017
- 2017-04-20 HR HRP20170622TT patent/HRP20170622T1/hr unknown
- 2017-04-25 CY CY20171100458T patent/CY1119356T1/el unknown
- 2017-09-27 US US15/717,624 patent/US10307414B2/en active Active
- 2017-12-27 JP JP2017252294A patent/JP6462842B2/ja active Active
-
2018
- 2018-04-06 HK HK18104553.1A patent/HK1245256B/zh unknown
-
2019
- 2019-04-03 US US16/374,430 patent/US20190224190A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR095198A1 (es) | Derivados de triazolona de piridinilo y piridinilo fusionado | |
AR092347A1 (es) | Derivados de azaindol | |
AR103297A1 (es) | Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina | |
AR102177A1 (es) | Compuestos de heteroarilo como inhibidores de btk y usos de los mismos | |
AR104025A1 (es) | Carbamatos de piperazina como moduladores de magl y/o abhd6, procesos para su preparación y composiciones farmacéuticas | |
AR103252A1 (es) | Compuestos de quinazolina | |
AR089865A1 (es) | Derivados de bencimidazol e imidazopiridinas como moduladores de canales de sodio | |
AR092742A1 (es) | Piridinonas antifibroticas | |
AR089285A1 (es) | Derivados de betulina | |
AR096748A1 (es) | Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina | |
AR093339A1 (es) | Analogos de spliceostatina y metodos para su preparacion | |
AR095359A1 (es) | Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina | |
AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
AR094299A1 (es) | Derivados de ftalazin-1(2h)-ona sustituidos | |
AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
AR100418A1 (es) | Compuestos y composiciones para inducir condrogénesis | |
AR096332A1 (es) | Compuestos heterocíclicos tricíclicos condensados como inhibidores de la integrasa del vih | |
AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR100806A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR090587A1 (es) | Compuestos triciclicos sustituidos con actividad hacia los receptores ep1 | |
AR103232A1 (es) | ANTAGONISTAS DE TGFbR | |
AR092288A1 (es) | Ligandos del receptor ep1 | |
AR107321A1 (es) | Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos | |
AR098621A1 (es) | Derivados de heteroarilo | |
AR095570A1 (es) | Derivados de urea |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |